Cargando…
Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report
BACKGROUND: The use of tyrosine kinase inhibitors (TKIs) of ALK is the therapy of choice for ALK-fusion patients. Unfortunately, all patients under this kind of treatment eventually develop acquired resistance through several well-known mechanisms, such as acquisition of a secondary mutation within...
Autores principales: | De Carlo, Elisa, Schiappacassi, Monica, Urbani, Martina, Doliana, Roberto, Baldassarre, Gustavo, Da Ros, Valentina, Santarossa, Sandra, Chimienti, Emanuela, Berto, Eleonora, Fratino, Lucia, Bearz, Alessandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292407/ https://www.ncbi.nlm.nih.gov/pubmed/30573982 http://dx.doi.org/10.2147/OTT.S184745 |
Ejemplares similares
-
Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018) -
Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
por: Bearz, Alessandra, et al.
Publicado: (2014) -
The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022) -
Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer
por: Stanzione, Brigida, et al.
Publicado: (2023) -
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
por: Bertoli, Elisa, et al.
Publicado: (2023)